BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AGA Medical Corporation (AGAM) Wins Injunction Against Occlutech's Figulla Flex; Bailiff Seizes Infringing Devices at Manufacturing Facility in Jena, Germany


11/2/2009 6:36:27 AM

Bookmark and Share

MINNEAPOLIS--(BUSINESS WIRE)--AGA Medical Holdings, Inc. today announced that the German Regional Court in Düsseldorf, Germany has granted a preliminary injunction against the manufacture, possession and sale of the Figulla® Flex occluders manufactured by Occlutech GmbH in Jena, Germany. The judge determined that the Figulla® Flex occluders infringe AGA Medical’s patent EP 0 808 138 in Germany. On October 29, a bailiff was sent to Occlutech’s facility in Jena and seized over 2,700 infringing devices.

As a result of this decision and the prior decisions of the German courts, Occlutech GmbH is now prevented from selling any of its occlusion products in Germany or producing them for sale outside of Germany. The injunction was granted soon after the German Federal Patent Court in Munich upheld the validity of AGA Medical’s patent. Although these decisions are subject to appeal, they continue to be enforced in Germany.

About AGA Medical Corporation

AGA Medical Corporation, based in Plymouth, Minn., is a leader in developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Founded in 1995 by Dr. Kurt Amplatz, a former University of Minnesota professor and researcher, AGA Medical’s range of AMPLATZER® products help improve patient outcomes, reduce length of hospital stay and accelerate patient recovery times. AMPLATZER products significantly advanced the treatment of the most common congenital “holes in the heart,” such as atrial septal defects, patent foramen ovale and ventricular septal defects. More than 1,500 articles supporting the benefits of AMPLATZER products have been published in medical literature. AGA Medical Holdings markets AMPLATZER products in 112 countries worldwide. For more information, visit www.amplatzer.com.

Contact:

Padilla Speer Beardsley Kristen Spargo, 612-455-1741 Kspargo@psbpr.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES